Edition:
United Kingdom

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

25.50SEK
23 May 2018
Change (% chg)

-0.10kr (-0.39%)
Prev Close
25.60kr
Open
25.65kr
Day's High
25.65kr
Day's Low
25.30kr
Volume
1,205,910
Avg. Vol
446,250
52-wk High
41.68kr
52-wk Low
25.30kr

Chart for

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)
No analyst recommendations are available for .

Overall

Beta: 0.71
Market Cap(Mil.): kr3,270.22
Shares Outstanding(Mil.): 82.17
Dividend: 0.28
Yield (%): 0.70

Financials

  KARO.ST Industry Sector
P/E (TTM): 20.39 84.06 32.75
EPS (TTM): 1.95 -- --
ROI: 11.70 1.57 14.38
ROE: 15.82 2.43 16.07

BRIEF-Karo Pharma Determines Terms For Rights Issue

* THE TERMS FOR KARO PHARMA'S RIGHTS ISSUE HAVE BEEN DETERMINED

30 Apr 2018

BRIEF-Karo Pharma Q1 EBITDA rose to SEK 89 mln

* KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER

26 Apr 2018

BRIEF-Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue

* THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING

04 Apr 2018

BRIEF-Karo Pharma Intends To Propose Dividend Of SEK 0.30 Per Share

* INTENDS TO PROPOSE DIVIDEND OF SEK 0.30 PER SHARE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

03 Apr 2018

BRIEF-Karo Pharma Acquires Major Product Portfolio for EUR 260 Mln

* ‍ACQUIRES A PRODUCT PORTFOLIO FROM DANISH PHARMACEUTICAL COMPANY LEO PHARMA A/S FOR 260 MEURO​

01 Mar 2018

BRIEF-Karo Pharma AB Q4 Adjusted EBITDA Rises To SEK 41.8 Mln

* Q4 NET SALES SEK 238.7 MILLION VERSUS SEK 96.5 MILLION YEAR AGO

22 Feb 2018

BRIEF-Karo Pharma Says RORgamma Project Is Not Shut Down

* SAYS RORGAMMA PROJECT IS NOT SHUT DOWN BUT CARRIES ON AS PLANNED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Jan 2018

BRIEF-Karo Pharma Rights Issue Subscribed To 170 Percent

* RIGHTS ISSUE SUBSCRIBED TO 170 PERCENT WITH PROCEEDS AT ABOUT SEK 794.3 MILLION BEFORE ISSUE COSTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

04 Jan 2018

BRIEF-Karo Pharma: New Issue To Provide Up To SEK 794.3 Ml‍n Before Issue Costs

* SAYS NEW ISSUE TO PROVIDE UP TO SEK 794.3 ML‍N BEFORE ISSUE COSTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Dec 2017

BRIEF-Karo Pharma Chairman Called For Inquiry For Inside Trading

* CHAIRMAN CALLED IN TO INQUIRY FROM POLICE FOR INSIDE TRADING

30 Nov 2017

Earnings vs. Estimates